Navigation Links
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
Date:4/9/2009

BEIJING, April 9 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's unaudited financial results for the three and twelve month periods ended December 31, 2008.

    Full Year 2008 Financial Highlights
    -- Record full year 2008 sales increasing 39% year-over-year to $46.5
       million
    -- Sold 6.93 million doses of Healive(R) in 2008, up from 5.12 million in
       2007
    -- Record full year net income growing of 5% to $8.01 million
    -- Full year EPS is $0.19
    -- Cash and cash equivalents increased 93% to $32.9 million, compared to
       the beginning of 2008, due to an increase in operation profits,
       improved accounts receivable collection and raising capital.

    Business Highlights
    -- In 2008, Sinovac initiated the development program of a vaccine against
       enterovirus 71 (EV 71), which causes hand, foot and mouth disease.
       Development is progressing on schedule and good achievements have been
       made to date.  Sinovac expects to file clinical trial application with
       China SFDA in 2009.
    -- Recognizing the sizeable market opportunity for animal vaccines,
       Tangshan Yian, Sinovac's wholly owned subsidiary, is focusing on the
       animal vaccine business to help drive growth.  In January 2009, the
       Company obtained approval from China's Ministry of Agriculture to
       conduct field trials of internally developed inactivated animal rabies
       vaccine.  Sinovac expects the field trials to take approximately nine
       months to complete and to launch the vaccine in China's veterinary
       market in 2010.
    -- Sinovac completed the pre-clinical trial for the Japanese encephalitis
       vaccine in 2008 and filed the clinical trial application with SFDA in
 
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ... Bina Technologies, Inc. (Bina), a privately held company ... , USA. Bina provides a big data platform ... sequencing (NGS) data. Bina,s proprietary on-market Genomic Management ... academic researchers to perform fast and scalable analyses ...
(Date:12/19/2014)... 2014 Decision Resources Group finds that the ... 12 percent compound annual growth rate through 2023. This ... and the increasing adoption of dental implants. Growing aesthetic ... also spur demand for dental biomaterials because they can ... treatments. Other key findings from Decision Resources ...
(Date:12/19/2014)... Altamonte Springs, FL (PRWEB) December 18, 2014 ... one of the nation’s leading specialty pharmacies, has ... who serve as clinical pharmacy consultants for prescriber ... disease therapy expertise. , “We have a ... disease therapies. For example, those specializing in hepatitis ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... Institutional Private Placement -, - $10 Million Principal Amount of Debt ... ... Stock -, DALLAS, Nov. 8 Access Pharmaceuticals, ... a $19.5 million recapitalization. The Company has entered,into agreements with institutional ...
... announced,the addition of Mr. Robert A. Ingram as Special ... and the hiring of Mr. Marty Glick as Executive ... Pharmaceuticals at GlaxoSmithKline (plc),and previously served as Chief Executive ... Glaxo Wellcome. Mr. Ingram,is Chairman of the Board of ...
... --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT),announced ... were $6,214,712,an increase of 567% over $930,442 in the ... third quarter of 2007 were $2,957,972 an increase of,226% ... These significant,increases are due to the growth of Kiwa,s ...
Cached Biology Technology:Access Pharmaceuticals Announces $19.5 Million Recapitalization 2Access Pharmaceuticals Announces $19.5 Million Recapitalization 3Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 3Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 4Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 5Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 6Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 7Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 8Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 9
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... ARTICLE #1 FOR IMMEDIATE RELEASE Lead leaching ... Science & Technology Scientists in Virginia are ... (PVC) plastic pipes may be more susceptible to leaching ... types of piping especially when PVC systems include ...
... June 2, 2008 UT Southwestern Medical Center ... pancreatic beta cells can regenerate after being induced to ... future insights into improved treatments of diabetes, which affects ... mouse, mimics what occurs in humans with type 1 ...
... already imperiled sturgeons, more caviar will be exported from ... a result of unacceptably permissive new trade quotas announced ... Species (CITES). Most sturgeon species are endangered and some, ... will further damage this ancient fish,s chance of recovery ...
Cached Biology News:American Chemical Society's Weekly PressPac -- May 28, 2008 2American Chemical Society's Weekly PressPac -- May 28, 2008 3American Chemical Society's Weekly PressPac -- May 28, 2008 4American Chemical Society's Weekly PressPac -- May 28, 2008 5American Chemical Society's Weekly PressPac -- May 28, 2008 6American Chemical Society's Weekly PressPac -- May 28, 2008 7Mouse model developed at UT Southwestern mimics hyperglycemia, aids in diabetes research 2Mouse model developed at UT Southwestern mimics hyperglycemia, aids in diabetes research 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4
... solid. PROTECT FROM LIGHT. PACKAGED UNDER ... that acts as a selective, reversible ... (IC 50 = 4 μM ... and PTP1B 298 , respectively). ...
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... immunowash microplate washer 100-240 V, is used ... U-, or V-bottom wells. The immunowash microplate ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
Biology Products: